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Abstract 
Ascorbic acid is an important antioxidant in human blood. Erythrocytes contribute to the antioxidant capacity of blood by regenerating 
ascorbate and possibly by exporting ascorbate-derived reducing equivalents through a transmembrane oxidoreductase. The role of 
ascorbate as an electron donor to the latter enzyme was tested in human erythrocytes and ghosts using nitroblue tetrazolium as an electron 
acceptor. Although nitroblue tetrazolium was not directly reduced by ascorbate, erythrocyte ghosts facilitated reduction of nitroblue 
tetrazolium in the presence of ascorbate and ascorbate derivatives containing a reducing double bond. The resulting blue monoformazan 
product was deposited directly in ghost membranes. Ascorbate-induced monoformazan deposition showed several features of an 
enzyme-mediated process, including hyperbolic dependence on substrate and acceptor concentrations, as well as sensitivity to enzyme 
proteolysis, detergent soluhilization, and sulfhydryl reagents. Incubation of intact erythrocytes with nitroblue tetrazolium caused 
deposition of the monoformazan i  ghost membranes prepared from the cells. This deposition reflected the intracellular scorbate content 
and was inhibited by extracellular ferricyanide, a known electron acceptor for the transmembrane oxidoreductase. Although nitroblue 
tetrazolium did not cross the cell membrane, like the cell-impermeant ferricyanide, it oxidized intracellular [ ~4C]ascorbate o [~4C]dehy- 
droascorbate, which then exited the cells. In resealed ghosts, both monoformazan deposition and ferricyanide reduction were proportional 
to the intravesicular scorhate concentration. NADH was only about half as effective as a donor for the enzyme as ascorbate in both open 
and resealed ghosts. These results uggest that not only can ascorbate donate lectrons to a transmembrane oxidoreductase, but that it may 
be the major donor in intact erythrocytes. 
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1. Introduction 
Ascorbic acid, or vitamin C, is considered one of the 
most important antioxidants in human serum [1,2]. About 
30% of ascorbate in whole blood is carried in erythrocytes 
[3]. In contrast to other cell types, in which ascorbate 
concentrations may be many-fold higher than in plasma 
[4], intracellular erythrocyte ascorbate concentrations are 
the same as those in plasma [3,5]. However, an intra- 
cellular recycling mechanism may provide many more 
ascorbate reducing equivalents for the antioxidant reserve 
of whole blood than suggested by the ascorbate concentra- 
tion alone. 
Abbreviations: NBT, nitroblue tetrazolium; PBS, phosphate-buffered 
saline. 
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The concept of ascorbate recycling by erythrocytes [6] 
received experimental support from the work of Orringer 
and Roer [7], who showed that intracellular ascorbate 
concentrations correlated with the ability of human 
erythrocytes to reduce extracellular ferricyanide. Ferri- 
cyanide is a mild oxidant that does not cross the erythro- 
cyte plasma membrane [8,9]. In the original hypothesis [7], 
a molecule of ascorbate released from cells directly re- 
duces two molecules of ferricyanide. The resulting dehy- 
droascorbate reenters the cells and undergoes reduction 
back to ascorbate via an NADH- [7] or GSH-dependent 
[ 10,11 ] process. In support of this model, dehydroascorbate 
is rapidly taken up by erythrocytes, either on the glucose 
[4,12] or another transporter [13]. Further, when added to 
an erythrocyte suspension, dehydroascorbate enhances ex- 
tracellular ferricyanide reduction [7,14]. Against the model 
is the fact that exit of ascorbate from cells is very slow 
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[15,16], at least in the absence of an extracellular oxidant. 
Further, Schipfer et al. [14] found no evidence for ferri- 
cyanide-induced release of ascorbate from intact erythro- 
cytes. Therefore, a mechanism other than transport of 
ascorbate itself must be considered to explain the transfer 
of ascorbate reducing equivalents out of erythrocytes. 
Erythrocytes possess a transmembrane oxidoreductase 
activity (E.C. 1.6.99.3) that can use extracellular ferri- 
cyanide as an acceptor for electrons derived from NADH 
[17,18]. Such an enzyme might mediate the ascorbate-de- 
pendent ferricyanide reduction observed in intact erythro- 
cytes [7,14]. To account for ascorbate-mediated electron 
transfer, the enzyme must be able to use ascorbate as well 
as NADH. However, testing directly whether ascorbate can 
serve as an electron donor to ferricyanide is not possible in 
isolated membranes or in purified enzyme preparations. 
This is because ascorbate itself quantitatively reduces ferri- 
cyanide in solution [7,14]. A different electron acceptor 
must be used to test the hypothesis that ascorbate is a 
substrate for the transmembrane oxidoreductase. Zamudio 
et al. [17] showed that nitroblue tetrazolium (NBT) is 
reduced by NADH in the presence of erythrocyte mem- 
branes. They also found that the precipitate of the mono- 
formazan was deposited in the membranes, leading them to 
suggest that the enzyme responsible was located within the 
membrane. We reasoned that NBT, which is typically used 
as an electron acceptor from superoxide [19], might serve 
as a suitable acceptor for ascorbate lectrons in this sys- 
tem. In this work we show that erythrocyte membranes do 
accelerate reduction of NBT in the presence of ascorbate, 
and that the monoformazan is deposited in the erythrocyte 
membrane. The monoformazan of NBT is also deposited 
in the plasma membranes of intact erythrocytes and re- 
sealed ghosts in a way that is dependent on the intra- 
cellular ascorbate concentration and that is inhibited by 
ferricyanide. These results suggest hat one or more trans- 
membrane oxidoreductases mediate the transfer of elec- 
trons from intracellular ascorbate to extracellular oxidants. 
2. Experimental procedures 
2.1. Materials 
Solid [1-14 C]ascorbic acid (4.7 Ci/mol) was obtained 
from New England Nuclear. Ascorbate oxidase, superox- 
ide dismutase, dehydroascorbate, ascorbate 6-palmitate, 
NBT, and o-isoascorbate were obtained from Sigma, St. 
Louis, MO. NBT was stored as a 58 mM solution in 
dimethylsulfoxide at 4°C. A working solution of NBT was 
prepared just before each assay by dilution into 
phosphate-buffered saline (PBS), which consisted of deion- 
ized, distilled water, containing 140 mM NaC1, 12.5 mM 
Na2PO 4, pH 7.4. The amount of dimethylsulfoxide in the 
assay depended on the NBT concentration. At a final NBT 
concentration of 116 /zM in the assay, the concentration of
dimethylsulfoxide was 0.2% (v/v).  
2.2. Preparation of  human erythrocytes, ghosts, and mem- 
branes 
Human erythrocytes were prepared from heparinized 
blood drawn from normal volunteers. The cells were 
washed three times in ten volumes of PBS, with careful 
removal of the buffy coat. Sometimes cells were stored up 
to 48 h in autologous erum at 4°C before use. Erythrocyte 
ghosts that had been depleted of cytoskeletal proteins were 
prepared according to the method described by Gorga and 
Lienhard [20]. Resealed impermeable rythrocyte ghosts 
were prepared from intact cells as described by Steck and 
Kant [21]. Reconstituted erythrocyte band 4.5 (nomencla- 
ture of Fairbanks et al. [22]) was prepared by chromatog- 
raphy over diethylaminoethyl cellulose according to the 
method of Baldwin et al. [23], as previously described [24]. 
This method removes the band 3 anion transporter and 
allows reconstitution of the remaining intrinsic membrane 
proteins into endogenous erythrocyte lipids. The predomi- 
nant protein in these vesicles is the band 4.5 glucose 
transporter, GLUT1 [23]. Protein content of erythrocyte 
ghosts and reconstituted band 4.5 was determined by the 
BCA method (Pierce). 
2.3. Measurement of  NBT reduction in erythrocyte ghosts 
and membranes 
In a typical assay, 50 /zl of erythrocyte ghosts (60-200 
/xg) or purified band 4.5 (25-60 /zg) were incubated for 
60 min at 37°C in a total volume of 0.5 ml of PBS 
containing 58-116 /~M NBT and other additives as indi- 
cated. The samples were mixed by swirling every few 
minutes. At the end of the assay, the samples were diluted 
to 1 ml with PBS and the absorbance at 560 nm was read 
in a Gilford Model 250 spectrophotometer. The absorbance 
reading of the sample was corrected for absorbance of a 
membrane sample incubated with NBT under identical 
conditions, but without ascorbate. In the absence of ery- 
throcyte membranes, incubation of 100 /xM ascorbate or 
NADH with 100 /xM NBT for 1 h at 37°C resulted in an 
absorbance that was less than 10% of that observed in the 
presence of membranes. Essentially all of the detectible 
color was in the ghost membranes, ince removal of the 
ghosts by centrifugation resulted in a supernatant with less 
than 2% absorbance compared to a membrane suspension 
(data not shown). The two-electron reduced monoformazan 
is considered the major reduction product of NBT under 
the conditions used [25], and it has a molar extinction 
coefficient of 10800 M -l cm -1 [26]. Thus in a typical 
experiment with 100 /xg of ghost protein incubated in the 
presence of 100 /zM ascorbate and 58 /zM NBT, 4.6 /zM 
monoformazan or about 10% of the NBT was deposited in 
the membrane after 1 h of incubation. However, the data 
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have not been presented as molar values, due to the 
confounding effects of deposition of the product in the 
lipid bilayer. 
2.4. Assay of erythrocyte f rricyanide reduction 
Resealed erythrocyte ghosts containing the indicated 
agent were washed three times in 10 volumes of PBS 
containing 5 mM D-glucose. For measurement of ferri- 
cyanide reduction, packed ghosts (0.1 ml) were diluted to 
1 ml with PBS containing 5 mM D-glucose and 100 /zM 
ferricyanide. The ghost suspension was incubated at 37°C 
in a shaking water bath. At the indicated times, 0.2 ml 
aliquots of ghosts and buffer were removed and mi- 
crofuged for 1 min. An aliquot of 0.1 ml of the supematant 
was sampled and the ferrocyanide content was measured 
by the assay of Avron and Shavit [27], using an assay 
volume of 1 ml. The amount of ferrocyanide was deter- 
mined from its optical density at 510 rim, using an extinc- 
tion coefficient of 10500 M -~ cm -~ for the 1,10-phenan- 
throline complex [27]. Following correction for absorbance 
of the ghost-conditioned PBS at 510 nm, the amount of 
ferrocyanide generated was expressed relative to the aque- 
ous resealed ghost space [7]. 
2.5. Measurement of radiolabeled ascorbate efflux from 
e~throcytes 
Effiux of [14C]dehydroascorbate from erythrocytes was 
measured as follows. Erythrocytes at a 40% hematocrit n 
PBS containing 5 mM D-glucose were loaded with 100-200 
/xM [14C]dehydroascorbate for 10 rain at room tempera- 
ture. Ascorbate oxidase (2 units/ml) was used to generate 
[14C]dehydroascorbate from [14C]ascorbate added to the 
cell suspension. In the absence of cells, this concentration 
of ascorbate oxidase completely converts 200 /xM 
[ 14 C]ascorbate to [ 14 C]dehydroascorbate within 5 min (data 
not shown). Following the loading step, extracellular ra- 
dioactivity was removed by washing the cells three times 
by centrifugation i ten volumes of PBS containing 5 mM 
D-glucose. Over 90% of the radioactivity was retained by 
the cells under these conditions. It has been demonstrated 
previously by infrared spectroscopy that the retained form 
of ascorbate is reduced ascorbate and not dehydroascorbate 
[16]. Packed cells were pipetted into microfuge tubes and 
effiux was initiated by vigorously diluting the cells with 22 
volumes of the same buffer at 37°C. The assay was 
terminated by another 5-fold dilution with ice-cold PBS 
containing 0.1 mM phloretin. The cells were pelleted in a 
microfuge and an aliquot of the medium was counted for 
radioactivity released from the cells. 
2.6. HPLC measurement and identification of ascorbate 
and dericatices 
Aliquots of the efflux medium from cells containing 
ascorbate or ascorbate metabolites labeled with carbon-14 
were chromatographed by HPLC using the reverse-phase 
ion-pair HPLC method of Pachla and Kissinger [28]. An 
aliquot of 0.2 ml of the effiux medium in a 1.4 ml 
microfuge tube was treated with 0.4 ml of ice-cold 15% 
trichloroacetic acid, vortexed vigorously, and allowed to 
sit on ice for 10 min. The solution was microfuged for I 
min in a Beckman Model B microfuge and the supernatant 
was extracted five times with 0.4 ml of diethyl ether to 
remove the trichloroacetic acid. Residual traces of ether 
were removed under a stream of nitrogen and the sample 
was placed on ice until measurement within 3 h. A 100 /xl 
aliquot of the extract was injected onto a Waters DeltaPak 
C~8 column (300/xm, 5 /xm). This mobile phase consisted 
of 70 mM ammonium acetate, 1 mM tridecylamine, and 
15% methanol, pH 5.2. Labeled fractions were collected 
over 30 s intervals and counted for radioactivity. At a flow 
rate of 1 ml/min, labeled or unlabeled ascorbate luted at 
5.8-6.2 min. The sensitivity for unlabeled ascorbate was 
200 pmol using UV detection at 254 rim. Elution of 
[ J4C]dehydroascorbate occurred just after the void volume, 
at 1.7 min, whereas the presumed breakdown product of 
dehydroascorbate, 2,3-diketogulonic acid [29], eluted at 
7.9-8.3 min. 
Attempts to directly measure the ascorbate content of 
intact erythrocytes by the above method were unsuccess- 
ful, due to oxidation of intracellular ascorbate to dehydro- 
ascorbate during cell lysis and extraction. Use of other 
protein precipitants (90% methanol or 50 mM perchloric 
acid), addition of chelating agents (e.g., I mM EDTA) 
[30], and displacement of oxygen from hemoglobin by 
carbon monoxide before lysis [31] showed similar results. 
Erythrocyte ascorbate has typically been estimated as the 
dinitrophenyl hydrazones of dehydroascorbate and 2,3-di- 
ketogulonic acid [3,32], perhaps for this reason. 
2. Z Data analysis 
Except where noted, results are expressed as mean _+ 
standard error for the indicated number of experiments, in
which duplicate or triplicate determinations were made. 
Statistical comparisons were made using the Student's 
paired t-test. Data fitting was carried out using the nonlin- 
ear curve-fitter in the graphics analysis package Axum 
(TriMetrix, Seattle, WA). 
3. Results 
3.1. Reduction of NBT and deposition of the monofor- 
mazan in erythrocyte membranes 
Incubation of increasing amounts of erythrocyte ghosts 
with 58 /xM NBT and 100 /xM ascorbate for 1 h at 37°C 
resulted in deposition of the monoformazan reduction 
product of NBT in the ghost membranes (Fig. 1). This was 
detected as an increase in UV absorbance a 560 nm. 
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Fig. 1. Deposition of the monoformazan of NBT with increasing amounts 
of ghost membranes. Erythrocyte ghost membranes were incubated with 
58 p,M NBT and 100 /xM ascorbate for 1 h at 37°C and the amount of 
monoformazan deposited in the membrane was determined as described 
under Experimental procedures. The data are from four experiments. 
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Fig. 2. Effects of temperature on the time-course of monoformazan 
deposition in ghost membranes. Ghost membranes (200 /zg/assay) were 
incubated with 58 /xM NBT and 100 /xM ascorbate in 5 mM phosphate 
buffer, pH 8.0, either at 23°C (squares) or at 37°C (circles). At the 
indicated times, the amount of monoformazan deposited was measured as 
described under Experimental procedures. The results shown are from 
four experiments. 
Deposition of the monoformazan increased with increasing 
concentrations of ghosts up to about 140 /xg of ghost 
protein, beyond which the rate of deposition decreased. At 
higher ghost concentrations, the amounts of ascorbate or 
NBT may have become limiting. The effects of incubation 
at 23°C or 37°C on monoformazan deposition in ghost 
membranes are shown in the Fig. 2. At both temperatures 
the rate of monoformazan deposition was rapid over the 
first 10 min, reaching a plateau after about 15-20 min. 
Incubation at 23°C lowered the initial rate of monofor- 
mazan deposition by half that seen at 37°C. All subsequent 
assays were performed at 37°C. 
The amount of monoformazan deposited in ghost mem- 
branes showed an hyperbolic dependence on the concentra- 
tion of ascorbate, NADH and NBT (data not shown). 
Kinetic parameters for the two donors and the acceptor are 
provided in Table 1. The apparent K m values for NADH 
and ascorbate were similar, although the maximal amount 
of monoformazan deposited with ascorbate was almost 
twice that seen with NADH as the donor. With ascorbate 
as the electron donor, the apparent affinity of NBT of 41 
/xM was lower than for the electron donors (Table 1). 
The specificity of NBT reduction was evaluated by 
assessing the effects of ascorbate derivatives, enzyme 
treatments, detergent solubilization, and sulfhydryl reagents 
on monoformazan deposition (Table 2). The stereoisomer 
of L-ascorbate, D-isoascorbate, enhanced monoformazan 
deposition to the same extent as ascorbate. Neither ascor- 
bate 2-sulfate nor dehydroascorbate caused an appreciable 
change in membrane color over that due to NBT alone. 
These results indicate that the reducing double bond struc- 
ture of ascorbate is necessary for the observed effect, but 
that stereospecificity is not required. Monoformazan depo- 
sition with ascorbate 6-palmitate as the electron donor was 
Table 1 
Kinetic parameters of the transmembrane oxidoreductase 
Experimental variable Km(/xM) Vn~ 
Ascorbate (7) 21 5:7 1.7 5:0.3 
NADH (4) 13 5:4 0.9 +_ 0.2 
NBT (6) 41 5:7 1.7-1-0.4 
Rates of monoformazan deposition in erythrocyte ghost membranes were 
measured at 10 min as described under Experimental procedures. When 
ascorbate and NADH were substrates, the concentration of NBT was 116 
/xM. Measurement of parameters for NBT was performed at an ascorbate 
concentration of 100 /xM. Results are shown for the number of experi- 
ments indicated in parentheses. The Vma x values are given as the change 
in absorbance per 10 min per mg of ghost protein. With increasing 
concentrations of both ascorbate and NADH there was a small amount of 
NBT converted to the monoformazan i the absence of ghosts, and this 
was corrected for with the use of reagent blanks in each assay. 
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greater than observed with ascorbate. This lipophilic ascor- 
bate derivative had a higher background of reduction of 
NBT in the absence of membranes (about 30% of the 
total), but even when correction was made for this effect, 
monoformazan deposition was clearly increased with this 
derivative. 
The effects of several enzymes on ascorbate-mediated 
NBT reduction are also shown in Table 2. Superoxide 
dismutase did not modify the extent of monoformazan 
deposition, indicating that superoxide was not the mediator 
of the effect. Treatment of erythrocyte ghosts with either 
trypsin or chymotrypsin decreased the amount of monofor- 
mazan deposited in the ghost membranes by 40% of that 
observed in controls. Incubation of intact erythrocytes with 
40 /xg /ml  trypsin or chymotrypsin for 30 min at 37°C had 
no effect on monoformazan deposition in erythrocyte ghosts 
prepared from these cells (data not shown). These results 
suggest hat at least part of the electron transfer activity is 
due to a protein exposed on the cytoplasmic face of the 
membrane. 
Monoformazan deposition in ghost membranes in the 
presence of ascorbate was sensitive to detergent solubiliza- 
tion of the membranes. Solubilitization of ghosts in either 
octyl-B-D-glucopyranoside or Triton X-100 increased ab- 
sorbance at 560 nm several-fold, as shown in Table 2. On 
the other hand, SDS essentially abolished NBT reduction. 
Similar results were found with NADH as the electron 
Table 2 
Formazan deposition in ghost membranes: effects of substrates, enzymes, 
and detergents 
Additive Fraction of control n 
Ascorbate 2-sulfate (100/.tM) 
D-Isoascorbate ( 100 /aM) 
Ascorbate 6-palmitate (100 /.tM) 
Dehydroascorbate (100 /.t M) 
Superoxide dismutase (100 units/ml) 
Trypsin (40/zg/ml) 
Chymotrypsin (40/.~g/ml) 
Octyl-B-D-glucopyranoside (38 raM) 
Triton X-100 (0.3%) 
SDS (0.05%) 
N-Ethylmaleimide (2 mM) 
p-CMB (20 ~M) 
p-CMBS (20/tM) 
0.16_+0.06 *
1.22_+ 0.2 
3.3 _+0.3 * 
0.08 -+ 0.0 
0.95 -4- 0.03 
0.6 -+0.06 * 
0.6 _+0.1 * 
4.2 -+0.5 * 
2.7 _+0.3 * 
0.1 _+0.1 ~ 
0.59+_0.04 *
0.53 _+ 0.09 * 
0.61 "4-0.1 * 
Where added, ascorbate was 100 /xM, NBT was 58 or 116 /xM, and 
there was 100-200 /xg of ghost protein in each assay. Incubations with 
dehydroascorbate lso contained two units of ascorbate oxidase to ensure 
absence of contaminating ascorbate. Proteinases and thiol reagents were 
incubated with ghost membranes for 30 rain at 37°C, followed by two 
centrifugation washes in 1 ml of fresh 5 mM sodium phosphate buffer, 
pH 8.0, and assay of monoformazan deposition. The mercurials were 
p-chloromercuribenzoate (p-CMB) and its sulfonate (p-CMBS). Data are 
expressed as a fraction of an ascorbate-treated control performed in the 
same experiment. An ' * '  indicates P < 0.05 versus incubation with 
ascorbate, n = number of experiments. 
Table 3 
Comparison of NBT reduction by ascorbate and NADH in protein-de- 
pleted ghosts and in purified band 4.5 
Membrane preparation Ascorbate (100/xM) NADH (I00/xM) 
Ghosts 0.06 ± 0.001 0.03 ± 0.001 * 
Band 4.5 0.28+0.02 0.16+0.01 *
Erythrocyte ghosts and purified band 4.5 were incubated at the same 
protein concentration (60 /xg/ml) with 116 /xM NBT and 100 /zM 
ascorbate or 100 /xM NADH1 h at 37°C in PBS, followed by measure- 
ment of monoformazan deposition as described under Experimental pro- 
cedures. Data are shown from three experiments, with an asterisk (' *') 
indicating P < 0.01 compared to the ascorbate-treated preparation. 
donor (data not shown). When freshly prepared, neither 
octyl-B-o-glucopyranoside nor Triton X-100 reduced NBT 
in the presence of ascorbate alone (data not shown). 
Treatment of ghost membranes with any of several 
sulfhydryl reagents irreversibly inhibited monoformazan 
deposition (Table 2). The inhibition shown for each 
sulfhydryl reagent is the maximal observed. The observed 
inhibitions uggest that the protein-mediated electron trans- 
fer requires one or more sulfhydryls for full activity. Lack 
of a more extensive inhibition by the sulfhydryl reagents 
indicates that the process involved is only partially sensi- 
tive to sulfhydryl blockade, or that more than one reducing 
process is involved. 
To further assess the hydrophobicity and exposure of 
the oxidoreductase, rythrocyte ghosts were solubilized in 
44 mM octyl-glucoside and passed over a small column of 
diethylaminoethyl cellulose. This treatment results in a 
preparation depleted of proteins with regions of exposed 
negative charge, such as the band 3 anion transporter [23]. 
Reconstitution of the unbound proteins in endogenous 
erythrocyte lipids and removal of octyl-B-D-glucoside by 
dialysis resulted in a preparation that had almost fivefold 
greater NBT reducing activity than observed for erythro- 
cyte ghosts at the same protein concentration (Table 3). 
Further, monoformazan deposition with NADH was only 
about half that observed with ascorbate in either ghosts or 
in reconstituted band 4.5. Thus, the higher maximal effect 
of ascorbate compared to NADH persists in a reconstituted 
preparation. These results also suggest either that the spe- 
cific activity of the enzyme(s) involved was increased in 
the band 4.5 preparation, or that the activity was more 
accessible in the reconstituted state. 
The results thus far indicate that ascorbate-associated 
monoformazan deposition in erythrocyte membranes is 
mediated by one or more enzymes that are cryptic in the 
membrane. However, they do not show the sidedness of 
the process with respect o the membrane bilayer. This was 
investigated by measuring monoformazan deposition in 
intact erythrocytes and resealed ghosts containing varying 
amounts of ascorbate. 
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Fig. 3. NBT reduction by intact erythrocytes. Erythrocytes at a 20% 
hematocrit were incubated in PBS containing 5 mM D-glucose and the 
indicated concentration f NBT for 1 h at 37°C with mixing. The cells 
were pelleted, white erythrocyte ghosts were prepared, and resuspended 
in 1 ml of 5 mM sodium phosphate buffer (pH 8.0) for measurement of 
monoformazan deposition. No hemolysis was observed in the first or 
subsequent washes of the cells. Although deposition of the monofor- 
mazan in the membrane prevented accurate measurement of ghost pro- 
tein, no differences were observed inthe sizes of ghost membrane p llets. 
Data are shown from two experiments. 
3.2. Reduction of NBT by intact erythrocytes 
The results of several different types of experiments 
suggest hat extracellular NBT uses intracellular ascorbate 
as an electron donor. First, addition of increasing amounts 
of extracellular NBT to freshly prepared erythrocytes con- 
taining endogenous ascorbate resulted in monoformazan 
deposition in ghost membranes that were subsequently 
prepared from these cells (Fig. 3). No monoformazan was 
detected in dilutions of the initial cellular lysate, nor was 
methemoglobin formation observed (not shown). These 
results suggest that NBT does not appreciably enter the 
cytoplasm under these conditions. 
Second, a 10 min incubation with 100 /zM dehydro- 
ascorbate in the presence of 5 mM D-glucose increased 
subsequent monoformazan deposition by 1 .5_  0.2-fold 
over that observed in untreated cells (n = 6 experiments, 
P < 0.01). As noted for [14C]dehydroascorbate under Ex- 
perimental procedures and previously by others [13,33] 
dehydroascorbate is rapidly transported across the erythro- 
cyte membrane and converted intracellularly to ascorbate 
[13,33]. Enhanced NBT reduction in such ascorbate-pre- 
loaded cells strongly suggests that at least part of the NBT 
reduction requires ascorbate as an electron donor. 
Third, in cells preloaded with [14C]ascorbate, NBT 
added to the extracellular space caused effiux of radiolabel 
(Fig. 4). Control cells lost only about 8% of intracellular 
[~4C]ascorbate following a 30 min incubation at 37°C. At a 
concentration of 100 /zM, ferricyanide caused a rapid loss 
of radioactivity from the cells over the first 5 min of 
incubation. The same concentration of NBT induced 
markedly slower release of radiolabel. At 400 /zM NBT, 
the release of radioactivity was greater, but with a distinct 
time lag. In other experiments, HPLC analysis of the 
radioactivity that had effluxed into the extracellular medium 
revealed only [14C]dehydroascorbate; no [laC]ascorbate or 
2,3-[~4C]diketogulonic acid was detected from control or 
oxidant-treated cells. These results suggest hat both ferri- 
cyanide and NBT induce an oxidant stress across the 
erythrocyte membrane, although the effect of NBT is 
smaller than with ferricyanide. Since ferricyanide is a 
stronger oxidant than NBT, it is not surprising that ferri- 
cyanide caused a much greater loss of [14C]dehydroascor - 
bate than did NBT. 
In the experiment of Fig. 4, it is likely that [14C]dehy- 
droascorbate l ft the cells primarily on the glucose trans- 
porter, since 10 /xM cytochalasin B inhibited the oxidant- 
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Fig. 4. Release of [14C]dehydroascorbate fromintact cells induced by 
NBT and ferricyanide. Erythrocytes preloaded with [14C]ascorbate w re 
incubated at37°C in PBS without additions (circles), with 100 /xM NBT 
(squares), with 400 /zM NBT (diamonds), orwith 100 /xM ferricyanide 
(triangles). At the indicated times, aliquots of cells were taken for 
measurement of radiolabel ffiux as described under Experimental proce- 
dures. The calculated [~4C]ascorbate concentration inside the cells at the 
start of the effiux assay in this experiment was 166 /.LM. The results 
shown are from one of two such experiments performed. 
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induced loss of radiolabel from ascorbate-loaded rythro- 
cytes by more than 80% (not shown). It should be noted 
that during the efflux phase of this experiment, cells were 
incubated without D-glucose. When 5 mM o-glucose was 
present, no efflux of radiolabel was evident at even the 
highest NBT concentration, and the effect of ferricyanide 
was also attenuated (see below). In the presence of an 
energy source, intracellular recycling of dehydroascorbate 
to ascorbate appears to be adequate to maintain low dehy- 
droascorbate concentrations, o that little [~4C]dehydro- 
ascorbate is released. 
The possibility that NBT and ferricyanide reduction are 
mediated by the same mechanism was tested as follows. 
Intact erythrocytes were incubated in the presence of NBT 
and increasing concentrations of ferricyanide, followed by 
preparation of ghost membranes and measurement of NBT 
reduction. It is apparent from Fig. 5 that extracellular 
ferricyanide progressively inhibited monoformazan deposi- 
tion in ghost membranes, with a half-maximal effect ob- 
served at 200 /zM ferricyanide. Only part of this effect 
could be due to ferricyanide-induced oxidation of ascor- 
bate within the cells, since in the presence of 5 mM 
D-glucose, only about 30% of radiolabeled ascorbate is lost 
from cells in dilute solution (results not shown). Accord- 
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Fig. 5. Inhibition of monoformazan deposition i intact cells by treatment 
with ferricyanide. Erythrocytes were incubated ata 25% hematocrit in 
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hemolysis was evident following the incubations. Results from two or 
more experiments at each ferricyanide concentration areexpressed asa 
fraction of the amount of monoformazan deposited incells treated with 
NBT alone. 
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Fig. 6. NBT reduction by resealed erythrocyte ghosts loaded with ascor- 
bate. An 0.2 ml aliquot of packed, washed erythrocytes was lysed with 
the addition of 40 volumes of ice-cold 5 mM phosphate buffer (pH 8.0) 
containing 1 mM MgSO 4 and the indicated concentration f ascorbic 
acid. Resealing ofthe ghosts was accomplished by addition of NaCI to a 
final concentration of 150 mM and warming the cells at 37°C for 1 h. The 
resealed ghosts were washed three times at 4°C by centrifugation at 
15000× g in 40 ml of PBS, and incubated with 116 /zM NBT for 30 
min at 37°C. The extent of monoformazan deposition i the ghosts was 
measured as described under Experimental procedures. The reading for 
each sample treated with NBT was corrected for absorbance of the ghost 
preparation alone. The results of three xperiments are shown, with the 
solid line depicting the results of curve-fitting to a hyperbolic model. 
ingly, most of the ferricyanide-induced inhibition of NBT 
reduction in intact cells appears due to direct competition 
between NBT and ferricyanide for the transmembrane 
enzyme. 
3.3. Effects of  loading resealed erythrocvte ghosts with 
ascorbate or NADH 
The role of ascorbate in mediating the deposition of the 
monoformazan i  the cell membrane of intact erythrocytes 
was tested directly in the experiments shown in Fig. 6, in 
which resealed erythrocyte ghosts were loaded with vary- 
ing amounts of ascorbate. Incubation of the resealed 'pink' 
ghosts with 116 /xM NBT resulted in progressively in- 
creasing amounts of the monoformazan deposited in the 
ghost membranes. Even without exogenous ascorbate, the 
monoformazan was deposited in the membranes of re- 
sealed ghosts. This background was likely due to endoge- 
nous ascorbate or NADH trapped within the ghosts during 
resealing. A kinetic analysis of such data is not possible, 
since the ascorbate concentration i side the ghosts will be 
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Fig. 7. Comparison fNBT and ferricyanide r duction i resealed ghosts 
preloaded with ascorbate or with NADH. Experimental procedures and 
conditions were those described in the legend to Fig. 6. In Panel A, 
ghosts were resealed to contain o additions ('CONTROL'), 400 p,M 
ascorbate ('ASC-400'), 100 /zM NADH ('NADH-100'), and 400 /xM 
NADH ('NADH-400'). The amount of monoformazan deposition in 
resealed ghost membranes from three experiments is shown for each 
treatment. An asterisk ('* ') indicates P < 0.05 compared to control 
ghosts. In Panel B, resealed ghosts were loaded in the same manner as in 
Panel A and incubated with 100 /xM ferricyanide for the indicated times 
before sampling of the suspension for ferrocyanide production as de- 
scribed under Experimental procedures. The circles represent control 
ghosts, the squares represent ghosts resealed with 100 /xM NADH, the 
diamonds represent ghosts resealed with 400 /xM NADH, and the 
triangles represent ghosts resealed with 400 /.tM ascorbate. Results from 
three xperiments are shown. 
constantly changing during the assay. However, these re- 
suits are in accord with the notion that intravesicular 
ascorbate can donate electrons to NBT, resulting in deposi- 
tion of its monoformazan derivative in the erythrocyte 
membrane. 
We then compared the abilities of NADH and ascorbate 
trapped in resealed ghosts to reduce extracellular NBT and 
ferricyanide. Ghosts resealed in the presence of 400 /zM 
ascorbate had a highly significant increase in monofor- 
mazan deposition, whereas ghosts resealed with the same 
concentration of NADH contained less than half the mono- 
formazan observed with ascorbate (Fig. 7A). Even 400 at 
/xM NADH, the increase in monoformazan deposition 
failed to reach statistical significance in the three experi- 
ments performed. Similar experiments were performed 
with ascorbate- or NADH-containing resealed ghosts, us- 
ing extracellular ferricyanide as the electron acceptor. In 
Fig. 7B it is evident that the same relationship was ob- 
served, with 400 /.tM ascorbate showing a greater effect 
than the same concentration of NADH. These results sug- 
gest that ascorbate is a natural donor for the transmem- 
brane oxidoreductase, and that it may be the preferred 
donor to NADH. 
4. Discussion 
In this work we provide evidence that ascorbate is a 
donor for a transmembrane oxidoreductase activity in hu- 
man erythrocytes. This activity has usually been studied 
with NADH as the electron donor and ferricyanide as the 
electron acceptor, and has been termed NADH:ferricyanide 
oxidoreductase [18,34,35]. It is differentiated from 
NADH:cytochrome b5 reductase activity by its kinetic 
features and by its transmembrane, as opposed to cytoso- 
lic, orientation [35,36]. The NADH:ferricyanide oxido- 
reductase has been purified from erythrocyte membranes 
and shown to migrate in SDS-polyacrylamide gel elec- 
trophoresis with an M r = 40000. The enzyme has a K m 
for NADH of 14 /zM [34], and is inhibited by exogenous 
proteinases and sulfhydryl reagents [37]. In open ghosts the 
enzyme was found to be cryptic, since its activity was 
increased many-fold by dissolution of the membranes in 
nonionic detergents [17,38]. Because of its transmembrane 
orientation and ability to donate electrons to ferricyanide, 
it is likely that this enzyme mediates the extracellular 
reduction of ferricyanide by intact erythrocytes [7,9,14]. 
Since the extent of ferricyanide reduction in intact erythro- 
cytes has been shown to parallel the intracellular ascorbate 
concentration [7,14], it is reasonable to consider whether 
ascorbate may be a natural or even the most important 
electron donor for this enzyme. 
To approach this question, we needed to study the 
enzyme activity in membrane preparations where concen- 
trations of electron donors and acceptors could be better 
controlled than in the intact cell. Ferricyanide rapidly 
oxidizes ascorbate in solution [7,14], so its reduction could 
not be used to follow ascorbate-dependent zyme activity 
in open membranes. On the other hand, we found that 
ascorbate does not reduce NBT to an appreciable xtent at 
physiologic pH. Zamudio et al. [17] had previously used 
NBT to document he location of the NADH-dependent 
oxidoreductase in erythrocyte membranes. NBT is a redox 
dye used extensively in the detection of superoxide release 
in biologic systems [19]. The complete reduction of NBT 
involves transfer of four electrons to produce the difor- 
mazan. However, when the NBT concentration is much 
greater than that of the ultimate electron acceptor, molecu- 
lar oxygen, the final product of NBT reduction is the 
monoformazan [25]. This compound has accepted two 
electrons and retains one of the two positive charges of 
nitroblue tetrazolium. It is poorly soluble in aqueous olu- 
tions. However, as noted by Zamudio et al. [17], the 
monoformazan is preferentially deposited in the lipid bi- 
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layer of erythrocyte membranes. This feature allows easy 
visual or spectrophotometric detection of the reaction, but 
complicates quantitation of the reaction rate. Despite our 
inability to calculate reaction rates, use of the NBT-based 
assay in ghost membranes showed that ascorbate served as 
an electron donor for an oxidoreductase with several fea- 
tures expected of the transmembrane NADH:ferricyanide 
oxidoreductase (Table 1 and Table 2). These include simi- 
lar substrate affinities, inhibition by sulfhydryl reagents 
and proteolytic enzymes, and enhancement following de- 
tergent solubilization. 
Additional evidence that ascorbate is a donor for the 
transmembrane oxidoreductase was obtained in studies 
using intact erythrocytes and resealed erythrocyte ghosts. 
In such preparations, it is critical to document hat NBT 
does not cross the cell membrane and enter the cytoplasm, 
where it could be reduced by an ascorbate- or NADH-de- 
pendent cytosolic enzyme, such as cytochrome-b 5 reduc- 
tase. In neutrophils the reduced monoformazan of NBT has 
been shown in electron microscopic studies to be deposited 
as a thin layer on the extracellular face of the plasma 
membrane, or within phagocytic granules, but not within 
the cytoplasm [39,40]. We were unable to detect either 
NBT or the reduced monoformazan i  lysates of erythro- 
cytes incubated with NBT. These considerations, along 
with the size and positive charge of NBT, make it highly 
unlikely that NBT crossed the cell membrane and was 
reduced inside cells in these studies. 
The monofonnazan of NBT was deposited in the cell 
membranes of intact erythrocytes incubated with NBT 
(Fig. 3), and this effect was enhanced by loading the cells 
with ascorbate. Both NBT and ferricyanide caused effiux 
of radiolabel as [14C]dehydroascorbate from cells loaded 
with [~4C]ascorbate (Fig. 4). Together, these data suggest 
that extracellular NBT oxidizes intracellular ascorbate via 
a transmembrane process. Since ferricyanide inhibited NBT 
reduction in intact cells (Fig. 5), the extracellular oxidants 
may work through similar mechanisms, with the observed 
inhibition resulting from competition for intracellular re- 
ducing equivalents derived from ascorbate or from NADH. 
Alternatively, since ferricyanide inhibited NBT reduction 
with a K~ similar to its own apparent K m of 120 /~M for 
reduction by erythrocytes [14], both acceptors may be 
competing for the same transmembrane enzyme. 
Our data also support he notion that ascorbate may be 
the major electron donor to the transmembrane oxido- 
reductase. At a concentration within the physiologic range 
(100 /xM), ascorbate consistently produced about twice as 
much monoformazan deposition in ghosts or reconstituted 
band 4.5 as the same concentration of NADH (Table 1 and 
Table 3). Also, when supraphysiologic concentrations of
ascorbate and NADH were resealed inside ghosts, both 
ferricyanide reduction and deposition of the monofor- 
mazan of NBT were about twice as large for ascorbate as 
observed for NADH (Fig. 7). The apparent K m for ascor- 
bate-induced monoformazan deposition of 21 /zM is in the 
lower range of the observed intracellular ascorbate concen- 
trations within erythrocytes in unsupplemented in ividuals, 
usually considered to be 25-60/zM [3]. A similar relation- 
ship exists for NADH, which has an apparent K m for 
ferricyanide reduction of 13 /~M [34], and an intracellular 
concentration i human erythrocytes of 14-40 /zM [41]. 
These considerations, and the fact that dietary ascorbate 
supplementation may raise plasma and erythrocyte ascor- 
bate concentrations above 100 /xM [3,42], suggest that 
ascorbate may be the major donor for the transmembrane 
oxidoreductase. 
The physiologic acceptor for the ascorbate- or NADH- 
dependent transmembrane oxidoreductase is unknown. It is 
possible that the enzyme serves to donate electrons to 
extracellular ascorbate free radical to regenerate ascorbate. 
as suggested by Schipfer et al. [14]. Alternatively, the 
transmembrane oxidoreductase may facilitate conversion 
of the Fe 3+ in diferric transferrin to Fe 2+, which is 
released from transferrin [43], and may be taken up and 
used by cells [44,45]. Since most cells take up transferrin 
through receptor-mediated endocytosis [46], a more likely 
possibility is that the transmembrane oxidoreductase func- 
tions in the endocytotic vesicle to reduce ferric to ferrous 
iron. Another possible acceptor of electrons from the trans- 
membrane oxidoreductase is lipid hydroperoxide in the 
lipid bilayer of the plasma membrane. Agutter and col- 
leagues [37,47] have suggested that an enzyme distinct 
from the NADH:ferricyanide oxidoreductase in erythrocyte 
membranes can donate electrons from NADH to exoge- 
nous lipid hydroperoxides incorporated into the erythro- 
cyte membrane bilayer. Although speculative, it is possible 
that such an enzyme could transfer electrons from intra- 
cellular ascorbate or NADH to membrane-resident a ti- 
oxidants, such as oxidized a-tocopherol [48,49] or 
ubiquinone- 10 [50]. 
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